USPTO Examiner SISSON BRADLEY L - Art Unit 1634

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17124214METHODS, PROBE SETS, AND KITS FOR DETECTION OF DELETION OF TUMOR SUPPRESSOR GENES BY FLUORESCENCE IN SITU HYBRIDIZATIONDecember 2020January 2024Abandon3711NoNo
17059927NUCLEIC ACID DETECTION METHODNovember 2020March 2024Abandon3960YesNo
17086203FAST-FORWARD SEQUENCING BY SYNTHESIS METHODSOctober 2020January 2023Abandon2730YesYes
17037594PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020April 2023Allow3140YesYes
17025763METHODS AND SYSTEMS FOR REDUCING PHASING ERRORS WHEN SEQUENCING NUCLEIC ACIDS USING TERMINATION CHEMISTRYSeptember 2020February 2024Abandon4120YesNo
16963063METHYLATION MARKERS FOR MELANOMA AND USES THEREOFJuly 2020August 2024Abandon5320NoNo
16960138METHOD AND SYSTEM FOR SUPERCOILING DNAJuly 2020May 2023Abandon3440YesNo
16916305APTAMER METHODJune 2020February 2023Allow3110NoNo
16957400METHOD OF COLLECTING NUCLEIC ACIDJune 2020March 2023Allow3320YesNo
16880706METHODS OF ATTACHING ADAPTERS TO SAMPLE NUCLEIC ACIDSMay 2020May 2023Abandon3520YesYes
16879214MOLECULAR TAGGING SYSTEM WITH NANOPORE-ORTHOGONAL DNA BARCODESMay 2020August 2023Abandon3911YesNo
16877964METHODS AND SYSTEMS FOR PROCESSING NUCLEIC ACID MOLECULESMay 2020August 2023Abandon3920NoNo
16876709METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLEMay 2020February 2023Abandon3340YesNo
16876682METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLEMay 2020January 2023Abandon3240YesYes
16864971FAST-FORWARD SEQUENCING BY SYNTHESIS METHODSMay 2020April 2023Abandon3501NoNo
16857005CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEMApril 2020January 2023Abandon3301NoNo
16851009METHOD FOR VERIFYING BIOASSAY SAMPLESApril 2020October 2023Abandon4221NoNo
16651932RAPID IN SITU DETECTION OF DNA AND RNAMarch 2020May 2024Abandon5040YesNo
16826035BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICEMarch 2020September 2023Abandon4220YesNo
16822012IDED DOUBLE-STRANDED PROBES FOR DETECTION OF NUCLEIC ACID AND USES OF SAMEMarch 2020September 2023Abandon4211NoNo
16820255THERMAL CALIBRATIONMarch 2020October 2023Abandon4320NoNo
16798704LABELING METHOD FOR NUCLEIC ACIDFebruary 2020August 2022Allow3010NoNo
16781409TRIMETHYLAMINE COMPOUNDS AS RISK PREDICTORS OF CARDIOVASCULAR DISEASEFebruary 2020March 2024Allow5010YesNo
16720205Gradient Structures Interfacing Microfluidics and Nanofluidics, Methods for Fabrication and Uses ThereofDecember 2019January 2023Abandon3710NoNo
16701119ULTRA SENSITIVE PROBES FOR DETECTION OF NUCLEIC ACIDDecember 2019June 2024Abandon5430NoNo
16593316NEUROFIBROMIN/DOPAMINE SIGNALING AS A BIOMARKER FOR COGNITIVE AND BEHAVIORAL PROBLEMS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)October 2019April 2021Allow1810NoNo
16553843PLATFORM INDEPENDENT HAPLOTYPE IDENTIFICATION AND USE IN ULTRASENSITIVE DNA DETECTIONAugust 2019August 2023Abandon4820NoNo
16528760ENZYME- AND AMPLIFICATION-FREE SEQUENCINGAugust 2019March 2023Abandon4311NoNo
16478078METHODS FOR HAPLOTYPE AND DIPLOTYPE DETERMINATIONJuly 2019September 2023Abandon5020NoNo
16423657REAGENTS AND METHODS FOR POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDSMay 2019February 2022Allow3310YesNo
16421407FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOODMay 2019March 2023Abandon4620NoNo
16417109METHODS FOR DETECTING TARGET NUCLEIC ACIDS IN A SAMPLEMay 2019March 2022Abandon3401NoNo
16415617TARGETED NON-INVASIVE PRENATAL TESTINGMay 2019January 2023Abandon4420NoNo
16382532METHOD FOR DETECTING TARGET NUCLEIC ACID MOLECULEApril 2019March 2023Abandon4721NoNo
16378104METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDApril 2019April 2020Abandon1210NoNo
16362407METHODS AND SYSTEMS FOR REDUCING PHASING ERRORS WHEN SEQUENCING NUCLEIC ACIDS USING TERMINATION CHEMISTRYMarch 2019November 2020Abandon2010NoNo
16358185SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCINGMarch 2019March 2023Abandon4730NoNo
16328039METHOD FOR DETECTING MICROORGANISMS IN A SAMPLEFebruary 2019November 2022Abandon4440NoNo
16324836COMPOSITIONS AND METHODS FOR ANALYZING NUCLEIC ACIDS ASSOCIATED WITH AN ANALYTEFebruary 2019October 2022Abandon4510NoNo
16263726METHODS FOR REMOVAL OF ADAPTOR DIMERS FROM NUCLEIC ACID SEQUENCING PREPARATIONSJanuary 2019October 2022Allow4421YesNo
16263074REDUCTION OF SIGNAL FROM CONTAMINANT NUCLEIC ACIDSJanuary 2019July 2024Abandon6060YesNo
16320325DNA PROBES FOR IN SITU HYBRIDIZATION ON CHROMOSOMESJanuary 2019November 2023Abandon5810NoNo
16253715METHODS AND COMPOSITIONS FOR DISCRETE MELT ANALYSISJanuary 2019March 2022Allow3810NoNo
16319499METHODS AND KITS FOR ANALYZING DNA BINDING MOIETIES ATTACHED TO DNAJanuary 2019June 2021Abandon2810NoNo
16244049ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATIONJanuary 2019February 2024Abandon6050YesNo
16236599COMPARATIVE GENOMIC HYBRIDIZATION ON ENCODED MULTIPLEX PARTICLESDecember 2018September 2022Abandon4420NoYes
16227790DETECTION AND QUANTIFICATION OF RARE VARIANTS WITH LOW-DEPTH SEQUENCING VIA SELECTIVE ALLELE ENRICHMENT OR DEPLETIONDecember 2018May 2022Abandon4020YesNo
16302346METHOD FOR DETECTION OF A PCR PRODUCTNovember 2018July 2023Abandon5660YesNo
16165408DIAGNOSIS OF VIRAL INFECTIONS BY DETECTION OF GENOMIC AND INFECTIOUS VIRAL DNA BY MOLECULAR COMBINGOctober 2018November 2022Abandon4921NoNo
16093916METHODS FOR EARLY DETECTION OF CANCEROctober 2018January 2022Abandon3911NoNo
16160820USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENTOctober 2018January 2022Abandon3920NoNo
16093636SYSTEMS AND METHODS FOR DETECTING GENETIC ALTERATIONSOctober 2018February 2023Allow5221NoNo
16092820METHODS OF PREDICTING PREECLAMPSIA USING BIOMARKERSOctober 2018January 2022Allow4021NoNo
16152378NUCLEIC ACID SAMPLE PREPARATION METHODSOctober 2018June 2021Allow3330NoNo
16089496SURFACE-BASED DETECTION OF NUCLEIC ACID IN A CONVECTION FLOW FLUIDIC DEVICESeptember 2018August 2023Abandon5931NoNo
16086908USE OF AN AQUEOUS COMPOSITION FOR DISSOLVING BIOMOLECULES FROM A TISSUE SAMPLESeptember 2018September 2023Abandon6090YesNo
16075709METHOD FOR DETECTING TARGET NUCLEIC ACID AND NUCLEIC ACID PROBE USED THEREINAugust 2018April 2022Allow4420YesNo
16052538METHODS AND SYSTEMS THAT DETECT NUCLEIC-ACID TARGETSAugust 2018January 2024Allow6020YesYes
16048695SOLUTION FOR EXTRACTION OF RNAJuly 2018April 2023Allow5720YesYes
16048196NOVEL ADAPTOR FOR NUCLEIC ACID SEQUENCING AND METHOD OF USEJuly 2018March 2023Abandon5631NoNo
16073210METHOD FOR DECODING BASE SEQUENCE OF NUCLEIC ACID CORRESPONDING TO END REGION OF RNA AND METHOD FOR ANALYZING DNA ELEMENTJuly 2018February 2022Allow4220NoNo
16071977TARGET ANALYSIS METHOD AND TARGET ANALYSIS KIT FOR USE IN THE METHODJuly 2018February 2021Abandon3110NoNo
16071529Target Analysis Method and Target Analyzing ChipJuly 2018February 2021Abandon3110NoNo
15756944METHOD OF ISOLATING NUCLEIC ACIDJuly 2018November 2022Abandon5640YesNo
16070678METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTIONJuly 2018May 2024Allow6030YesYes
15756195COMPOSITION AND METHODS FOR DETECTING ADENOSINE MODIFICATIONSJuly 2018March 2022Allow4930YesNo
16023051METHODS OF SYNTHESIZING AND LABELING NUCLEIC ACID MOLECULESJune 2018February 2021Abandon3230NoNo
16016086COMPOSITIONS AND METHODS FOR DETECTING VIRAL NUCLEIC ACIDSJune 2018July 2021Abandon3720NoNo
16062639USE OF ANTISENSE LONG NON-CODING RNAS FOR THE DIAGNOSIS OF PROSTATE CANCERJune 2018October 2022Abandon5231YesNo
15985282CHEMICAL LIGATION DEPENDENT PROBE AMPLIFICATION (CLPA)May 2018May 2024Abandon6020YesYes
15978333Strain Typing Assay and Method Without Need for Isolation in Pure Form and Subsequent Longitudinal Strain TrackingMay 2018October 2021Abandon4140YesNo
15775393METHODS AND KITS FOR NUCLEIC ACID DETECTIONMay 2018January 2022Abandon4420NoNo
15972331OLIGONUCLEOTIDE DETECTION METHODMay 2018September 2020Abandon2940NoYes
15953316METHODS OF ATTACHING ADAPTERS TO SAMPLE NUCLEIC ACIDSApril 2018April 2022Allow4820NoYes
15920421METHODS OF DEPLETING OR ISOLATING TARGET RNA FROM A NUCLEIC ACID SAMPLEMarch 2018June 2020Abandon2711NoNo
15891316Methods and Compositions For Sorting and/or Determining OrganismsFebruary 2018January 2022Abandon4720NoNo
15888042Methods, Compositions and Kits for Detection of Mutant Variants of Target GenesFebruary 2018November 2021Abandon4521YesNo
15747130NUCLEIC ACID DETECTION METHODJanuary 2018March 2022Allow5030NoYes
15875385METHOD OF DETERMINING TARGET NUCLEIC ACIDJanuary 2018February 2023Allow6041YesNo
15746395LOCKED NUCLEIC ACIDS FOR CAPTURING FUSION GENESJanuary 2018March 2022Abandon5020NoNo
15746371SEQUENCE-INDEPENDENT NUCLEIC ACID ASSEMBLYJanuary 2018April 2021Abandon3920YesNo
15746328SYSTEMS AND METHODS OF GENETIC ANALYSISJanuary 2018November 2021Abandon4520NoNo
15869831METHOD OF UTILIZING ENZYME FOR ISOTHERMAL NUCLEIC ACID HYBRIDIZATIONJanuary 2018March 2020Abandon2710NoNo
15555054SIGNATURE OF HEALTHDecember 2017March 2022Abandon5451YesYes
15739301SELECTIVE DEGRADATION OF WILD-TYPE DNA AND ENRICHMENT OF MUTANT ALLELES USING NUCLEASEDecember 2017March 2023Allow6031YesNo
15739354BRANCHED PROXIMITY HYBRIDIZATION ASSAYDecember 2017January 2022Abandon4920NoNo
15738982COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING NANOSWITCHESDecember 2017April 2024Allow6071NoNo
15840871GENOME CAPTURE AND SEQUENCING FOR COMPREHENSIVE CHROMATIN STRUCTURE MAPS IN COMPLEX GENOMES AND CANCER PROGRESSIONDecember 2017November 2020Allow3510YesNo
15839795BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICEDecember 2017September 2019Allow2130YesYes
15578821NUCLEIC ACID DETECTIONDecember 2017January 2020Abandon2510NoNo
15579071IMPROVEMENTS IN AND RELATING TO NUCLEIC ACID PROBES AND HYBRIDISATION METHODSDecember 2017August 2023Abandon6061YesNo
15826035METHOD FOR OPTIMAL DESIGN OF POLYNUCLEOTIDES SEQUENCES FOR ANALYSIS OF SPECIFIC EVENTS IN ANY GENETIC REGION OF INTERESTNovember 2017February 2020Abandon2620NoNo
15824641OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USENovember 2017November 2019Abandon2310NoNo
15820798Method for Detecting Target Nucleic AcidNovember 2017January 2019Abandon1311NoNo
15573131ULTRA SENSITIVE PROBES FOR DETECTION OF NUCLEIC ACIDNovember 2017January 2020Abandon2610YesNo
15800291Methods of Hybridizing Probes to Genomic DNANovember 2017June 2020Abandon3110YesNo
15784855STOICHIOMETRIC TUNING OF NUCLEIC ACID HYBRIDIZATION PROBES BY AUXILIARY OLIGONUCLEOTIDE SPECIESOctober 2017May 2021Abandon4350YesYes
15729421COMPOSITIONS AND METHODS FOR THE DETECTION OF GENOMIC FEATURESOctober 2017June 2020Abandon3211NoNo
15724479METHODS AND SYSTEMS FOR DETECTING A NUCLEIC ACID IN A SAMPLE BY ANALYZING HYBRIDIZATIONOctober 2017August 2020Abandon3430YesNo
15559827IDED DOUBLE-STRANDED PROBES FOR DETECTION OF NUCLEIC ACID AND USES OF SAMESeptember 2017March 2020Abandon3011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SISSON, BRADLEY L.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
48
Examiner Affirmed
25
(52.1%)
Examiner Reversed
23
(47.9%)
Reversal Percentile
69.5%
Higher than average

What This Means

With a 47.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
253
Allowed After Appeal Filing
51
(20.2%)
Not Allowed After Appeal Filing
202
(79.8%)
Filing Benefit Percentile
27.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SISSON, BRADLEY L - Prosecution Strategy Guide

Executive Summary

Examiner SISSON, BRADLEY L works in Art Unit 1634 and has examined 816 patent applications in our dataset. With an allowance rate of 16.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner SISSON, BRADLEY L's allowance rate of 16.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SISSON, BRADLEY L receive 2.76 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SISSON, BRADLEY L is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +18.1% benefit to allowance rate for applications examined by SISSON, BRADLEY L. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 3.7% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 8.8% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 70.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.4% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 38.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 83.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.